A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants with Metastatic or Unresectable Solid Tumors with HER2-activating Mutations
Latest Information Update: 22 Jan 2025
Price :
$35 *
At a glance
- Drugs BAY 2927088 (Primary)
- Indications Biliary cancer; Bladder cancer; Cervical cancer; Colon cancer; Colorectal cancer; Endometrial cancer; Gallbladder cancer; Rectal cancer; Solid tumours; Urogenital cancer
- Focus Therapeutic Use
- Sponsors Bayer
- 13 Jan 2025 New trial record